Biotech Acquisition Company (BIOTU)

SAN FRANCISCO, August 01, 2022--Blade Therapeutics to participate in "Drug Development in Pulmonary Medicine" panel discussion on August 9 at the 2022 BTIG Biotechnology Conference

In more signs of trouble in the blank-check merger market, Blade Therapeutics cancelled its planned deal. Meanwhile another startup is preparing for a shareholder vote after offering a disappointing financial forecast.

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the "Merger Agreement"), effective immediately.

Even as some SPACs get tripped up, Senti plans to use its merger to push two cell therapies into clinical trials, sign more deals with gene therapy companies and open a manufacturing center in Alameda.

The company, which makes a blood glucose monitor, had planned to raise $75 million through its IPO. But a lot has changed since it filed its paperwork last fall.

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced the postponement of BAC's extraordinary general meeting of shareholders (the "Extraordinary Meeting") originally scheduled to be held on June 3, 2022. The Extraordinary Meeting has been postponed until a to-be determined later dat

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a submission to the United States Securities and Exchange Commission ("SEC") of a prospectus supplement containing information supplements and updates to the information contained in the proxy statement/prospectus dated May 9, 2022, included in Amendment No. 4 to the registration statement on Form S-4 (File No. 333-26

SOUTH SAN FRANCISCO, Calif., May 18, 2022--Blade Therapeutics announces new data from preclinical studies that highlight differentiating characteristics of cudetaxestat in poster at ATS 2022.

SOUTH SAN FRANCISCO, Calif., May 16, 2022--Blade Therapeutics presented data from phase 1 & preclinical DDI studies of cudetaxestat at American Thoracic Society 2022 International Conference

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, CA, today announced that the registration statement on Form S-4 (as amended, the "Registration Statement") filed in connection with BAC's and Blade's previously announced proposed business combination (the "Business Combination") has been declared effect

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, the first amendment to its registration statement on Form S-4, filed on March 15, 2022 (as amended, the "registration statement"), relating to its previously announced proposed business combination with Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical

SOUTH SAN FRANCISCO, Calif., April 04, 2022--Blade Therapeutics, Inc. ("Blade" or "Company"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases. The FDA response letter ou

SOUTH SAN FRANCISCO, Calif., March 24, 2022--Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that the company will present data for cudetaxestat in three posters at the American Thoracic Society (ATS) 2022 International Conference, May 13-18, 2022, The Moscone Center, in San Francisco. The poster presentations will include new data from a phase 1 drug-drug interaction cli

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, a registration statement on Form S-4 relating to its previously announced proposed business combination with Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., March 07, 2022--Blade to present at Oppenheimer’s 32nd Annual Healthcare Conference on March 15 and at Barclays Global Healthcare Conference on March 16, 2022.

Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor, joins Yahoo Finnace Live to discuss Walmart's choice to lift mask mandates for fully vaccinated employees, COVID-19 cases declining, and Pfizer pulling FDA filing for vaccines for children under five-years-old.

SOUTH SAN FRANCISCO, Calif., January 12, 2022--Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat.

Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential submission to the United States Securities and Exchange Commission ("SEC"), for receipt by the SEC on December 27, 2021, of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with Blade Therapeutics, Inc. ("Blade")

Juan Monteverde, founder and managing partner of the firm Monteverde & Associates PC ("M&A Firm"), a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Biotech Acquisition Company ("BIOT" or the "Company") (BIOT), relating to the proposed merger with Blade Therapeutics, Inc. Under the terms of the agreement, BIOT shareholders will retain only 36% of the combined compa

NEW YORK, NY / ACCESSWIRE / November 18, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. (NASDAQ:CBTX)Agreement Announcement: November 8, 2021 Transaction Details:Under the terms of the merger, Allegiance shareholders will receive 1.